NASDAQ:ANCNANCHIANO THERAP/S Stock Price, Forecast & News

$1.12

-0.06 (-5.08 %)

(As of 05/25/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.98

Now: $1.12▼

$1.20

50-Day Range

$0.66

MA: $0.88▼

$1.18

52-Week Range

$0.51

Now: $1.12▼

$5.25

Volume65,100 shs

Average Volume36,321 shs

Market Capitalization$8.31 million

P/E RatioN/A

Dividend YieldN/A

Beta0.87

Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Jerusalem, Israel.

Beat the Market (BTM) Rank^™

3.0 Analyst's Opinion

Consensus Rating
ANCHIANO THERAP/S has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.00, ANCHIANO THERAP/S has a potential upside of 1,150.0% from its current price of $1.12.
Amount of Analyst Coverage
ANCHIANO THERAP/S has received no research coverage in the past 90 days.

2.5 Community Rank

Outperform Votes
ANCHIANO THERAP/S has received 56 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ANCHIANO THERAP/S has received 57 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ANCHIANO THERAP/S has received 50.44% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ANCHIANO THERAP/S and other stocks. Vote “Outperform” if you believe ANCN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ANCN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ANCHIANO THERAP/S does not currently pay a dividend.
Dividend Growth
ANCHIANO THERAP/S does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ANCHIANO THERAP/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.88% of the stock of ANCHIANO THERAP/S is held by insiders.
Percentage Held by Institutions
Only 7.49% of the stock of ANCHIANO THERAP/S is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for ANCHIANO THERAP/S are expected to decrease in the coming year, from ($2.25) to ($3.00) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ANCHIANO THERAP/S is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ANCHIANO THERAP/S is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ANCHIANO THERAP/S has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.23 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ANCN

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.anchiano.com

Phone972-2548-6555

Debt

Debt-to-Equity Ratio0.01

Current Ratio4.23

Quick Ratio4.23

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.01 per share

Price / Book0.56

Profitability

EPS (Most Recent Fiscal Year)($3.46)

Net Income$-27,120,000.00

Net MarginsN/A

Return on Equity-54.04%

Return on Assets-33.83%

Miscellaneous

Employees19

Outstanding Shares7,420,000

Market Cap$8.31 million

Next Earnings Date8/3/2020 (Estimated)

OptionableNot Optionable

Receive ANCN News and Ratings via Email

Sign-up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.

ANCHIANO THERAP/S (NASDAQ:ANCN) Frequently Asked Questions

How has ANCHIANO THERAP/S's stock been impacted by COVID-19 (Coronavirus)?

ANCHIANO THERAP/S's stock was trading at $0.8191 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ANCN stock has increased by 36.7% and is now trading at $1.12. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ANCHIANO THERAP/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANCHIANO THERAP/S in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ANCHIANO THERAP/S.

When is ANCHIANO THERAP/S's next earnings date?

ANCHIANO THERAP/S is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for ANCHIANO THERAP/S.

How were ANCHIANO THERAP/S's earnings last quarter?

ANCHIANO THERAP/S (NASDAQ:ANCN) posted its quarterly earnings results on Tuesday, March, 17th. The company reported $1.99 earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $2.12. View ANCHIANO THERAP/S's earnings history.

What price target have analysts set for ANCN?

3 brokers have issued 1-year price objectives for ANCHIANO THERAP/S's shares. Their forecasts range from $12.00 to $16.00. On average, they anticipate ANCHIANO THERAP/S's stock price to reach $14.00 in the next year. This suggests a possible upside of 1,150.0% from the stock's current price. View analysts' price targets for ANCHIANO THERAP/S.

Has ANCHIANO THERAP/S been receiving favorable news coverage?

News stories about ANCN stock have trended negative on Tuesday, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ANCHIANO THERAP/S earned a news sentiment score of -2.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutANCHIANO THERAP/S.

Who are some of ANCHIANO THERAP/S's key competitors?

Some companies that are related to ANCHIANO THERAP/S include Hoth Therapeutics (HOTH), Akari Therapeutics (AKTX), Aerpio Pharmaceuticals (ARPO), Annovis Bio (ANVS), Mereo BioPharma Group (MREO), PLx Pharma (PLXP), AgeX Therapeutics (AGE), Dare Bioscience (DARE), Spring Bank Pharmaceuticals (SBPH), Correvio Pharma (CORV), Sernova (SEOVF), Alimera Sciences (ALIM), Neurotrope (NTRP), Edesa Biotech (EDSA) and Cyclacel Pharmaceuticals (CYCC). View all competitors.

What other stocks do shareholders of ANCHIANO THERAP/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANCHIANO THERAP/S investors own include AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Amplify Energy (AMPY), Amplify Energy (AMPY), Algonquin Power & Utilities (AQN), BCE (BCE), Franklin Resources (BEN), Bank of Nova Scotia (BNS), British American Tobacco (BTI) and Carnival (CCL).

Who are ANCHIANO THERAP/S's key executives?

ANCHIANO THERAP/S's management team includes the following people:

Dr. Frank G. Haluska, Pres, CEO & Director (Age 60)
Mr. Jonathan Burgin, CFO & COO (Age 58)
Mr. Ronald K. Knickerbocker, Sr. VP of Clinical Devel. & Data Sciences (Age 53)
Prof. Abraham Hochberg, Co-Founder & Chief Scientific Officer (Age 81)
Dr. Michal Gilon Ohev-Zion, VP of R&D (Age 41)

When did ANCHIANO THERAP/S IPO?

(ANCN) raised $35 million in an initial public offering on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

What is ANCHIANO THERAP/S's stock symbol?

ANCHIANO THERAP/S trades on the NASDAQ under the ticker symbol "ANCN."

How do I buy shares of ANCHIANO THERAP/S?

Shares of ANCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ANCHIANO THERAP/S's stock price today?

One share of ANCN stock can currently be purchased for approximately $1.12.

How big of a company is ANCHIANO THERAP/S?

ANCHIANO THERAP/S has a market capitalization of $8.31 million. The company earns $-27,120,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. ANCHIANO THERAP/S employs 19 workers across the globe.

What is ANCHIANO THERAP/S's official website?

The official website for ANCHIANO THERAP/S is www.anchiano.com.

How can I contact ANCHIANO THERAP/S?

ANCHIANO THERAP/S's mailing address is 1/3 HIGH-TECH VILLAGE GIVAT RAM P.0. BOX 39264, JERUSALEM L3, 9139102. The company can be reached via phone at 972-2548-6555 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff